Nutex Health Statistics
Total Valuation
Nutex Health has a market cap or net worth of $1.29 billion. The enterprise value is $1.43 billion.
| Market Cap | 1.29B |
| Enterprise Value | 1.43B |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutex Health has 6.85 million shares outstanding. The number of shares has increased by 14.84% in one year.
| Current Share Class | 6.85M |
| Shares Outstanding | 6.85M |
| Shares Change (YoY) | +14.84% |
| Shares Change (QoQ) | -2.20% |
| Owned by Insiders (%) | 32.87% |
| Owned by Institutions (%) | 35.66% |
| Float | 4.14M |
Valuation Ratios
The trailing PE ratio is 7.47 and the forward PE ratio is 7.02.
| PE Ratio | 7.47 |
| Forward PE | 7.02 |
| PS Ratio | 1.52 |
| Forward PS | 1.40 |
| PB Ratio | 3.25 |
| P/TBV Ratio | 3.57 |
| P/FCF Ratio | 4.72 |
| P/OCF Ratio | 4.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.84, with an EV/FCF ratio of 5.25.
| EV / Earnings | 7.93 |
| EV / Sales | 1.68 |
| EV / EBITDA | 2.84 |
| EV / EBIT | 2.96 |
| EV / FCF | 5.25 |
Financial Position
The company has a current ratio of 5.00, with a Debt / Equity ratio of 0.68.
| Current Ratio | 5.00 |
| Quick Ratio | 4.79 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | 0.69 |
| Debt / FCF | 1.28 |
| Interest Coverage | 24.33 |
Financial Efficiency
Return on equity (ROE) is 64.56% and return on invested capital (ROIC) is 61.92%.
| Return on Equity (ROE) | 64.56% |
| Return on Assets (ROA) | 33.32% |
| Return on Invested Capital (ROIC) | 61.92% |
| Return on Capital Employed (ROCE) | 56.79% |
| Weighted Average Cost of Capital (WACC) | 12.94% |
| Revenue Per Employee | $816,509 |
| Profits Per Employee | $173,499 |
| Employee Count | 1,037 |
| Asset Turnover | 0.94 |
| Inventory Turnover | 118.85 |
Taxes
In the past 12 months, Nutex Health has paid $70.99 million in taxes.
| Income Tax | 70.99M |
| Effective Tax Rate | 20.67% |
Stock Price Statistics
The stock price has increased by +104.50% in the last 52 weeks. The beta is 1.99, so Nutex Health's price volatility has been higher than the market average.
| Beta (5Y) | 1.99 |
| 52-Week Price Change | +104.50% |
| 50-Day Moving Average | 161.88 |
| 200-Day Moving Average | 136.17 |
| Relative Strength Index (RSI) | 61.09 |
| Average Volume (20 Days) | 159,318 |
Short Selling Information
The latest short interest is 1.10 million, so 16.13% of the outstanding shares have been sold short.
| Short Interest | 1.10M |
| Short Previous Month | 1.05M |
| Short % of Shares Out | 16.13% |
| Short % of Float | 26.64% |
| Short Ratio (days to cover) | 8.61 |
Income Statement
In the last 12 months, Nutex Health had revenue of $846.72 million and earned $179.92 million in profits. Earnings per share was $25.24.
| Revenue | 846.72M |
| Gross Profit | 461.53M |
| Operating Income | 481.27M |
| Pretax Income | 343.48M |
| Net Income | 179.92M |
| EBITDA | 502.27M |
| EBIT | 481.27M |
| Earnings Per Share (EPS) | $25.24 |
Balance Sheet
The company has $205.21 million in cash and $347.34 million in debt, with a net cash position of -$142.13 million or -$20.75 per share.
| Cash & Cash Equivalents | 205.21M |
| Total Debt | 347.34M |
| Net Cash | -142.13M |
| Net Cash Per Share | -$20.75 |
| Equity (Book Value) | 507.31M |
| Book Value Per Share | 57.62 |
| Working Capital | 468.43M |
Cash Flow
In the last 12 months, operating cash flow was $279.62 million and capital expenditures -$7.77 million, giving a free cash flow of $271.85 million.
| Operating Cash Flow | 279.62M |
| Capital Expenditures | -7.77M |
| Depreciation & Amortization | 21.00M |
| Net Borrowing | -22.63M |
| Free Cash Flow | 271.85M |
| FCF Per Share | $39.70 |
Margins
Gross margin is 54.51%, with operating and profit margins of 56.84% and 21.25%.
| Gross Margin | 54.51% |
| Operating Margin | 56.84% |
| Pretax Margin | 40.57% |
| Profit Margin | 21.25% |
| EBITDA Margin | 59.32% |
| EBIT Margin | 56.84% |
| FCF Margin | 32.11% |
Dividends & Yields
Nutex Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.84% |
| Shareholder Yield | -14.84% |
| Earnings Yield | 14.01% |
| FCF Yield | 21.18% |
Analyst Forecast
The average price target for Nutex Health is $266.40, which is 41.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $266.40 |
| Price Target Difference | 41.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 5.03% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 3, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Nutex Health has an Altman Z-Score of 3.88 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.88 |
| Piotroski F-Score | 5 |